As a Venture Partner at CDRD, Canada’s national life sciences venture, Dr. Crawford is responsible for overseeing and advancing a portfolio of drug development and commercialization projects through management of multi-disciplinary scientific and business teams. Prior to assuming this role, he was VP of Scientific Operations after joining CDRD as Head of Medicinal Chemistry in 2008.
Previously, from 1999-2007, he held a series of increasingly-senior positions at AnorMED Inc. – initially a Medicinal Chemist, and eventually the Manager of the Development Chemistry Group, leading the synthetic development of all lead and candidate compounds intended for use in pre-clinical and clinical trials. Notably, for plerixafor, which now generates over $150 million annually in global sales as Mozobil, he oversaw the technical transfer of the development process to a contract research organization, the subsequent clinical manufacture, and the eventual validation of the manufacturing process for commercial use. He also acted concurrently as an interdisciplinary project team leader for a clinical-stage anti-HIV therapeutic. In addition to his experience at AnorMED, Dr. Crawford also developed novel antibacterial agents in his role of Senior Scientist, Medicinal Chemistry at Microcide Pharmaceuticals Inc. based in Mountain View, California.
Dr. Crawford received his B.Sc. in chemistry/biochemistry in 1991, and a PhD in organic chemistry in 1996 from the University of Victoria (Canada). He then conducted post-doctoral research in organic synthesis at the Ohio State University from 1996-1997.